Thomas Pabst

103PUBLICATIONS

277CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsBiomechanical engineeringGene and molecular therapyPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (103)

Sort by Publication Date:

|Jul 15, 2026

Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.

|Jul 15, 2026

Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.

|Jul 01, 2026

Feasibility and safety of rapid glofitamab ramp-up.

|Jun 26, 2026

Influence of <i>PPM1D</i> Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients.

|Jun 19, 2026

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

|Jun 15, 2026

Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.

Pageof 18

Frequent Collaborators

66 joint publications

Vera Ulrike Bacher

29 joint publications

Katja Seipel

17 joint publications

Michael Daskalakis

13 joint publications

Henning Nilius

11 joint publications

Dilara Akhoundova

Markus G Manz

Gertrud Wiedemann

Bastian von Tresckow

Naomi Porret

Bob Löwenberg

Frequent Collaborators

66 joint publications

Vera Ulrike Bacher

29 joint publications

Katja Seipel

17 joint publications

Michael Daskalakis

13 joint publications

Henning Nilius